Click here to view Chinese version
Latest Share Price
29.50
0.00
29.50
0.00
Get the Flash Player to see this player.
Click here to view our new company videoPower of
Plants
Plants have long been
a reliable source of new
anti-infective and
anti-cancer
drugs. Using medicines
identified in China as a starting
point,
Phynova develops
Western pharmaceutical drugs
protected by the Company's own
intellectual property.
Drug Candidates
PYN17 HEPATITIS C
Chronic Hepatitis C
PYN22 NAFLD
For Non Alcoholic Fatty Liver Disease ('NAFLD')
PYN9 POI
For Post Operative Ileus
PYN6 MRSA
For MRSA and Acne
PYN18 HEPATITIS C
Hepatitis C Virus and Dengue
PYN7 CANCER
For Cancer
News
Phynova Announces Half-Yearly Results for Period Ended 31 March 2008
Phynova Group PLC ("Phynova" or the "Company") PHYNOVA ANNOUNCES HALF-YEARLY RESULTS FO...
Phynova presents data relating to PYN6 activity against MRSA at American Society For Microbiology
30 May 2008 Phynova Group PLC ("Phynova" or the "Company") PHYNOVA PRESENTS DATA RELAT...
Phynova Appoints John East & Partners and Capital MS&L
29 May 2008 Phynova Group PLC ("Phynova" or the "Company") PHYNOVA APPOINTS JOHN EAST ...
Pipeline
Phynova has identified a number of Drug Candidates in the fields of anti-virals, anti-microbials, anti-inflammatories and oncology. At present, it is concentrating its development efforts on six of these: PYN17, PYN22, PYN9, PYN6, PYN18 and PYN7.